H.I.G. BioHealth Partners

H.I.G. BioVentures invests in a broad range of life science companies across multiple sectors and stages of development. Their seasoned investment team has extensive and diverse experience in big pharma, small biotech, medical devices, diagnostics, basic science, clinical research, and technology transfer. They invest in companies developing novel products for significant unmet medical needs.

Bruce Robertson

Managing Director and Co-Head of BioHealth

Gwen Watanabe

Managing Director

Alex Zisson

Managing Director and Co-Head of BioHealth

26 past transactions

Click Therapeutics

Series B in 2021
Click Therapeutics, Inc. specializes in the engineering, validation, development, and commercialization of digital therapeutic solutions aimed at addressing unmet medical needs through cognitive and neurobehavioral modification. Founded in 2012 and based in New York, the company offers innovative digital therapeutics for a range of conditions, including smoking cessation, major depressive disorder, schizophrenia, insomnia, and chronic pain. Its Digital Therapeutics™ are designed to function independently or alongside traditional biomedical treatments, utilizing the Clickometrics® adaptive data science platform to personalize user experiences and enhance engagement. Notably, Click's smoking cessation program has gained widespread access through various payers and providers, while its primary prescription program is advancing into a significant phase III clinical trial for major depressive disorder in adults.

Arvelle Therapeutics

Series A in 2020
Arvelle Therapeutics GmbH, a biopharmaceutical company, focuses on solutions for patients suffering from CNS disorders. It is involved in the development and commercialization of cenobamate, an investigational antiepileptic drug in the European market. The company was founded in 2019 and is headquartered in Zug, Switzerland.

Zerigo Health

Series A in 2019
Zerigo Health, formerly known as Clarify Medical, Inc., specializes in home therapy solutions for chronic skin conditions such as psoriasis, eczema, and vitiligo. The company offers innovative products like the Clarify mobile ultra violet B treatment system and the Home Light Therapy System, both designed to facilitate phototherapy in a home setting. Zerigo Health aims to enhance the ease and effectiveness of UVB therapy through a connected system that allows patients to manage their treatment via a smartphone app. This app enables users to control dosing, frequency, and duration of therapy, ensuring adherence to guidelines set by dermatology experts. By allowing patients to administer their treatments with clinical precision, Zerigo Health improves the overall patient experience, while also monitoring compliance and progress, ultimately empowering individuals to manage their chronic skin conditions more effectively from the comfort of their homes.

Exagen

Venture Round in 2019
Exagen is a patient focused, discovery-driven life science company that addresses the unmet need for the accurate diagnosis and monitors patients affected by autoimmune rheumatic diseases. The company also provides AVISE tests that are specifically designed to provide objective information to physicians and patients for more accurate, efficient diagnosis, and better disease management. Exagen was established in 2002 and is headquartered in Vista, California.

Intact Vascular

Series D in 2019
Intact Vascular, Inc., a medical device company, develops medical devices for minimally invasive peripheral vascular procedures. The company offers Tack Endovascular System, a device that offers optimization of peripheral balloon angioplasty results during the treatment of peripheral arterial disease (PAD) and critical limb ischemia (CLI). Intact Vascular, Inc. was formerly known as Tackit Vascular LLC. The company was founded in 2011 and is based in Wayne, Pennsylvania.

Arvelle Therapeutics

Series A in 2019
Arvelle Therapeutics GmbH, a biopharmaceutical company, focuses on solutions for patients suffering from CNS disorders. It is involved in the development and commercialization of cenobamate, an investigational antiepileptic drug in the European market. The company was founded in 2019 and is headquartered in Zug, Switzerland.

Iconic Therapeutics

Venture Round in 2018
Iconic Therapeutics, Inc. operates as a biopharmaceutical company that translates tissue factor biology in angiogenesis, inflammation, and metastasis to develop new therapeutics for retinal disease and cancer. Its products include ICON-1, a fusion protein designed to address the basis of vision loss in age-related macular degeneration. Iconic Therapeutics, Inc. was incorporated in 2002 and is based in South San Francisco, California.

Neurana Pharmaceuticals

Series A in 2018
Neurana Pharmaceuticals, Inc. is a pharmaceutical company based in San Diego, California, focusing on the development of treatments for neuromuscular conditions. Founded in 2013, the company specializes in a novel therapeutic compound, Tolperisone, which addresses acute and painful muscle spasms in the neck and back as well as other musculoskeletal issues. Unlike traditional muscle relaxants, Tolperisone provides relief without causing sedation, offering a unique solution for patients experiencing spasticity and muscle discomfort.

Intact Vascular

Series C in 2018
Intact Vascular, Inc., a medical device company, develops medical devices for minimally invasive peripheral vascular procedures. The company offers Tack Endovascular System, a device that offers optimization of peripheral balloon angioplasty results during the treatment of peripheral arterial disease (PAD) and critical limb ischemia (CLI). Intact Vascular, Inc. was formerly known as Tackit Vascular LLC. The company was founded in 2011 and is based in Wayne, Pennsylvania.

On Target Laboratories

Series B in 2018
On Target Laboratories, LLC engages in discovering, developing, and commercializing small molecules that target specific pathological cells, when conjugated with fluorescent dyes. It offers folate and other targeting agents that target, lung, uterine, kidney, breast, colon, pancreatic, and prostate cancer cells. The company was incorporated in 2010 and is based in Northbrook, Illinois.

Vertiflex

Venture Round in 2017
VertiFlex Inc. is a medical device company focused on developing minimally invasive solutions for lumbar spinal stenosis (LSS). The company offers the Superion Interspinous Spacer, a motion-preserving spinal implant designed for the treatment of moderate LSS, and the Totalis Direct Decompression System, which includes specialized instruments for safely performing direct decompressions of the lumbar spine. Founded in 2005 and based in Carlsbad, California, VertiFlex operates both domestically and internationally. As of June 2019, it became a subsidiary of Boston Scientific Corporation, further enhancing its capabilities in the spinal surgery market.

Intact Vascular

Series B in 2017
Intact Vascular, Inc., a medical device company, develops medical devices for minimally invasive peripheral vascular procedures. The company offers Tack Endovascular System, a device that offers optimization of peripheral balloon angioplasty results during the treatment of peripheral arterial disease (PAD) and critical limb ischemia (CLI). Intact Vascular, Inc. was formerly known as Tackit Vascular LLC. The company was founded in 2011 and is based in Wayne, Pennsylvania.

Nutrinia

Series D in 2016
Nutrinia Ltd. is a neonatology company focused on developing pharmaceuticals for rare gastrointestinal conditions in infants. The company’s primary clinical programs include NTRA-2112, which addresses intestinal malabsorption in preterm infants by improving enteral nutrition tolerance, enhancing growth velocity, and reducing the length of stay in neonatal intensive care units. Another key product, NTRA-9620, targets short bowel syndrome by promoting bowel adaptation after surgical resection and minimizing reliance on parenteral nutrition. Nutrinia’s innovative approach includes oral formulations of insulin to support gut rehabilitation in infants. Founded in 2003 and based in Ramat-Gan, Israel, Nutrinia is dedicated to improving health outcomes for vulnerable populations.

Iconic Therapeutics

Series C in 2016
Iconic Therapeutics, Inc. operates as a biopharmaceutical company that translates tissue factor biology in angiogenesis, inflammation, and metastasis to develop new therapeutics for retinal disease and cancer. Its products include ICON-1, a fusion protein designed to address the basis of vision loss in age-related macular degeneration. Iconic Therapeutics, Inc. was incorporated in 2002 and is based in South San Francisco, California.

Orbus Therapeutics

Series A in 2015
They at Orbus are committed to bringing innovative products to the extremely underserved patients affected by rare diseases. They are focused and passionate about bringing a more positive outcome to patients facing life-threatening or significantly life-altering diseases. Currently, Orbus Therapeutics is working to develop and commercialize eflornithine in North America. The company was founded in 2012 and is headquartered in Palo Alto, California.

RxSight

Debt Financing in 2015
RxSight is a medical device company that offers an intraocular lens and cataract surgery solutions. Using a proprietary light treatment that produces precise modifications in lens curvature, RxSight’s Light Adjustable Lens (RxLAL) enables doctors and patients to predictably optimize vision after cataract surgery through an office-based IOL enhancement. The company’s mission is to revolutionize the premium cataract surgery experience by allowing surgeons to partner with their patients to achieve optimized results for every unique eye. It was founded in 1997 and is headquartered in Aliso Viejo, California, United States.

RxSight

Venture Round in 2015
RxSight is a medical device company that offers an intraocular lens and cataract surgery solutions. Using a proprietary light treatment that produces precise modifications in lens curvature, RxSight’s Light Adjustable Lens (RxLAL) enables doctors and patients to predictably optimize vision after cataract surgery through an office-based IOL enhancement. The company’s mission is to revolutionize the premium cataract surgery experience by allowing surgeons to partner with their patients to achieve optimized results for every unique eye. It was founded in 1997 and is headquartered in Aliso Viejo, California, United States.

NeuWave Medical

Series C in 2015
NeuWave Medical develops tools that deliver energy to the human body to treat a variety of serious medical conditions. Their company founders are both engineers and physician-scientists which allows determining a clinical need and design solutions that are clinically relevant, effective, and minimally invasive. They strive to make the highest quality devices that are the products of choice for leading physicians and medical centers around the world. The company was founded in 2004 and is headquartered in Madison, Wisconsin.

Intact Vascular

Series B in 2015
Intact Vascular, Inc., a medical device company, develops medical devices for minimally invasive peripheral vascular procedures. The company offers Tack Endovascular System, a device that offers optimization of peripheral balloon angioplasty results during the treatment of peripheral arterial disease (PAD) and critical limb ischemia (CLI). Intact Vascular, Inc. was formerly known as Tackit Vascular LLC. The company was founded in 2011 and is based in Wayne, Pennsylvania.

Cardeas Pharma

Series B in 2015
Cardeas Pharma is developing a novel antibiotic formulation of two drugs with synergistic activity against all relevant, highly resistant Gram-negative bacilli, including Pseudomonas aeruginosa, Acinetobacter baumannii, and carbapenem-resistant Enterobacteriaceae. In addition, this antibiotic formulation has activity on biofilms. The combination also has activity against Gram-positive pathogens including methicillin-resistant Staphylococcus aureus (MRSA). This formulation is administered using a single-patient use, vibrating-plate nebulizer that is compatible with all ventilators. The nebulizer creates small, uniform aerosol droplets that deliver drug to the small airways and alveoli. Integration of this novel antibiotic formulation and device has the potential to achieve significant clinical outcomes relative to current standard therapy.

ForSight VISION5

Series C in 2014
ForSight VISION5 was founded in 2010 as the fifth company created by the ophthalmic product incubator, ForSight Labs. ForSight VISION5 is developing non-invasive products that replace eye drops and provide sustained therapy for major eye diseases including glaucoma, dry eye, and allergy. The company is currently in its second Phase 2 clinical study for its lead product, the Helios insert.

ForSight Labs

Series C in 2014
ForSight Labs is focused on developing and applying solutions to improve the sight, care, and quality of life of visually impaired patients. Our environment is creative and collaborative; a place where entrepreneurs and investors work together to drive innovative technologies through concept, development, and ultimately commercialization in high-impact eye care companies (ForSight VISION companies). Each day millions of people rely on their vision and suffer when it is lost. There are few disabilities as impactful to quality of life as the loss of vision. The number of people with impaired vision in the US, including blindness, is expected to more than double over the next three decades. Recent estimates of the cost of vision loss in the US exceed $50 billion dollars annually. ForSight Labs brings together highly motivated and capable team members, clinicians and investors focused on starting and sustaining efforts to deliver innovative solutions to the ophthalmic community and the patients it serves.

Iconic Therapeutics

Series B in 2014
Iconic Therapeutics, Inc. operates as a biopharmaceutical company that translates tissue factor biology in angiogenesis, inflammation, and metastasis to develop new therapeutics for retinal disease and cancer. Its products include ICON-1, a fusion protein designed to address the basis of vision loss in age-related macular degeneration. Iconic Therapeutics, Inc. was incorporated in 2002 and is based in South San Francisco, California.

Cerephex

Series A in 2012
Cerephex is a company developing its proprietary RINCE technology for treatment applications involving noninvasive brain stimulation. Cerephex is currently engaged in development activities aimed at gaining FDA approval of its NeuroPoint device for the management of fibromyalgia, a chronic pain condition that involves abnormal central pain processing mechanisms.

NeuWave Medical

Series B in 2012
NeuWave Medical develops tools that deliver energy to the human body to treat a variety of serious medical conditions. Their company founders are both engineers and physician-scientists which allows determining a clinical need and design solutions that are clinically relevant, effective, and minimally invasive. They strive to make the highest quality devices that are the products of choice for leading physicians and medical centers around the world. The company was founded in 2004 and is headquartered in Madison, Wisconsin.

Intact Vascular

Series A in 2012
Intact Vascular, Inc., a medical device company, develops medical devices for minimally invasive peripheral vascular procedures. The company offers Tack Endovascular System, a device that offers optimization of peripheral balloon angioplasty results during the treatment of peripheral arterial disease (PAD) and critical limb ischemia (CLI). Intact Vascular, Inc. was formerly known as Tackit Vascular LLC. The company was founded in 2011 and is based in Wayne, Pennsylvania.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.